Our Story
Closing the gap between science and care
Closing the gap between science and care
Evident Medical was founded around a simple observation: modern science has transformed what we know about treating psychosis, but too few people benefit from these advances.
Over the past several decades, researchers around the world have developed better medications, better ways of monitoring recovery, and better models of care. Yet many individuals living with psychosis continue to receive treatment that does not fully reflect what is known to work.
For patients and families, this often means years of unnecessary symptoms, repeated hospitalizations, difficult side effects, and missed opportunities for recovery—not because better care does not exist, but because it is difficult to access.
Why We Believe This Matters
Throughout our clinical, academic, and research work, we have seen the same pattern repeatedly: the greatest challenge is often not discovering better treatments—it is making sure people actually receive them. Too often, effective treatments are introduced late, important side effects are not systematically monitored, progress is difficult to measure, and families are left without the guidance they need. We believe patients deserve better.
A Different Model of Care
Specialized expertise in psychosis
Evidence-based psychopharmacology
Measurement-based care
Structured monitoring
Collaboration with families and providers
A recovery-oriented and trauma-informed philosophy
About Our Founder
Jose M. Rubio, MD, PhD — Founder & Medical Director
Jose M. Rubio, MD, PhD
Founder & Medical Director
Dr Rubio is a board certified psychiatrist specializing in psychosis, with a track record of leading clinical and research programs in academic settings. Dr Rubio has 15+ years of experience treating psychosis in the framework of Coordinated Specialty Care. He has published 70+ research articles, with a focus on relapse prevention, treatment resistance, and personalized medicine. Dr Rubio has received recognition from the Schizophrenia International Research Society (SIRS), the American College of Neuropsychopharmacology (ACNP), and the American Psychiatric Association (APA) among other organizations. His research has been funded by industry and the National Institutes of Health (NIH).